These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 21508735

  • 1. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT, Viswanathan C, Erasmus JJ.
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [Abstract] [Full Text] [Related]

  • 2. Positron emission tomography imaging in nonsmall-cell lung cancer.
    Erasmus JJ, Macapinlac HA, Swisher SG.
    Cancer; 2007 Nov 15; 110(10):2155-68. PubMed ID: 17896784
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Value of FDG PET in the management of NSCLC.
    Ukena D, Hellwig D.
    Lung Cancer; 2004 Aug 15; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J.
    Int J Cancer; 2013 Jan 15; 132(2):E37-47. PubMed ID: 22890912
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
    Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR.
    J Thorac Cardiovasc Surg; 2003 Apr 15; 125(4):938-44. PubMed ID: 12698159
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 15; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 12. PET in lung cancer staging.
    Coleman RE.
    Q J Nucl Med; 2001 Sep 15; 45(3):231-4. PubMed ID: 11788815
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography.
    Al-Sarraf N, Aziz R, Doddakula K, Gately K, Wilson L, McGovern E, Young V.
    Interact Cardiovasc Thorac Surg; 2007 Jun 15; 6(3):350-3. PubMed ID: 17669863
    [Abstract] [Full Text] [Related]

  • 15. Imaging in lung cancer: positron emission tomography scan.
    Vansteenkiste JF.
    Eur Respir J Suppl; 2002 Feb 15; 35():49s-60s. PubMed ID: 12064681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu CS, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.
    J Thorac Oncol; 2011 Aug 15; 6(8):1367-72. PubMed ID: 21587082
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.